Lisdexamfetamine dimesylate.
Elia
Josephine
J
Easley
Chris
C
Kirkpatrick
Peter
P
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D003913:Dextroamphetamine / Q000627:therapeutic use*; D004298:Dopamine / Q000502:physiology; D017277:Drug Approval; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D009638:Norepinephrine / Q000502:physiology; D011355:Prodrugs / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D019966:Substance-Related Disorders / Q000523:psychology; D014481:United States; D014486:United States Food and Drug Administration
D000697:Central Nervous System Stimulants; D011355:Prodrugs; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine; D004298:Dopamine; D009638:Norepinephrine